Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track

Viking Therapeutics, Inc.

2022-Q2 EPS reported -$0.43

Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.
Cash, cash equivalents and short-term investments at $169M as of June 30, 2022.
VK2809 Phase 2b VOYAGE study for NASH/fibrosis; enrollment completion expected in 4Q 2022.
Phase 1 study of dual GLP-1/GIP agonist VK2735 ongoing; initial results expected by year-end 2022.
FDA clinical hold on VK0214 Phase 1b for X-ALD lifted; dosing to resume, data expected 1H 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.